Receptor-Assisted Nanotherapeutics for Overcoming the Blood-Brain Barrier.
BBB disruption
Blood–brain barrier
Nanomedicine
Nanotechnology
Receptors
Transporters
Journal
Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
30
11
2023
accepted:
03
02
2024
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
Blood-brain barrier (BBB) is a distinguishing checkpoint that segregates peripheral organs from neural compartment. It protects the central nervous system from harmful ambush of antigens and pathogens. Owing to such explicit selectivity, the BBB hinders passage of various neuroprotective drug molecules that escalates into poor attainability of neuroprotective agents towards the brain. However, few molecules can surpass the BBB and gain access in the brain parenchyma by exploiting surface transporters and receptors. For successful development of brain-targeted therapy, understanding of BBB transporters and receptors is crucial. This review focuses on the transporter and receptor-based mechanistic pathway that can be manoeuvred for better comprehension of reciprocity of receptors and nanotechnological vehicle delivery. Nanotechnology has emerged as one of the expedient noninvasive approaches for brain targeting via manipulating the hurdle of the BBB. Various nanovehicles are being reported for brain-targeted delivery such as nanoparticles, nanocrystals, nanoemulsion, nanolipid carriers, liposomes and other nanovesicles. Nanotechnology-aided brain targeting can be a strategic approach to circumvent the BBB without altering the inherent nature of the BBB.
Identifiants
pubmed: 38558360
doi: 10.1007/s12035-024-04015-9
pii: 10.1007/s12035-024-04015-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Reddy S, Tatiparti K, Sau S, Iyer AK (2021) Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors. Drug Discov Today 26:1944–1952. https://doi.org/10.1016/J.DRUDIS.2021.04.008
doi: 10.1016/J.DRUDIS.2021.04.008
pubmed: 33865978
Moura RP, Martins C, Pinto S, Sousa F, Sarmento B (2019) Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opin Drug Deliv 16:271–285. https://doi.org/10.1080/17425247.2019.1583205
doi: 10.1080/17425247.2019.1583205
pubmed: 30767695
Wang Y, Zhai W, Cheng S, Li J, Zhang H (2023) Surface-functionalized design of blood-contacting biomaterials for preventing coagulation and promoting hemostasis. Friction 11:1371–1394. https://doi.org/10.1007/S40544-022-0710-X/METRICS
doi: 10.1007/S40544-022-0710-X/METRICS
Wang Y, Peng F, Xie G, Chen ZQ, Li HG, Tang T, Luo JK (2016) Rhubarb attenuates blood-brain barrier disruption via increased zonula occludens-1 expression in a rat model of intracerebral hemorrhage. Exp Ther Med 12:250. https://doi.org/10.3892/ETM.2016.3330
doi: 10.3892/ETM.2016.3330
pubmed: 27347045
pmcid: 4907008
Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–236. https://doi.org/10.1007/S11481-006-9025-3/METRICS
doi: 10.1007/S11481-006-9025-3/METRICS
pubmed: 18040800
Campbell HK, Maiers JL, DeMali KA (2017) Interplay between tight junctions & adherens junctions. Exp Cell Res 358:39–44. https://doi.org/10.1016/J.YEXCR.2017.03.061
doi: 10.1016/J.YEXCR.2017.03.061
pubmed: 28372972
pmcid: 5544570
Haddad-Tóvolli R, Dragano NRV, Ramalho AFS, Velloso LA (2017) Development and function of the blood-brain barrier in the context of metabolic control. Front Neurosci 11:224. https://doi.org/10.3389/FNINS.2017.00224/BIBTEX
doi: 10.3389/FNINS.2017.00224/BIBTEX
pubmed: 28484368
pmcid: 5399017
Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19:1584–1596. https://doi.org/10.1038/nm.3407
doi: 10.1038/nm.3407
pubmed: 24309662
pmcid: 4080800
Begley D (2004) ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1295–1312. https://doi.org/10.2174/1381612043384844
doi: 10.2174/1381612043384844
pubmed: 15134482
Kooij G, van Horssen J, Bandaru VVR, Haughey NJ, de Vries HE (2012) The role of ATP-binding cassette transporters in neuro-inflammation: relevance for bioactive lipids. Front Pharmacol 3. https://doi.org/10.3389/fphar.2012.00074
Latif S, Kang YS (2022) Blood–brain barrier solute carrier transporters and motor neuron disease. Pharmaceutics 14:2167. https://doi.org/10.3390/PHARMACEUTICS14102167
doi: 10.3390/PHARMACEUTICS14102167
pubmed: 36297602
pmcid: 9608738
Hu C, Tao L, Cao X, Chen L (2020) The solute carrier transporters and the brain: physiological and pharmacological implications. Asian J Pharm Sci 15:131–144. https://doi.org/10.1016/J.AJPS.2019.09.002
doi: 10.1016/J.AJPS.2019.09.002
pubmed: 32373195
Pulgar VM (2019) Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci 13:1019. https://doi.org/10.3389/FNINS.2018.01019/BIBTEX
doi: 10.3389/FNINS.2018.01019/BIBTEX
Salarpour S, Barani M, Pardakhty A, Khatami M, Pal Singh Chauhan N (2022) The application of exosomes and exosome-nanoparticle in treating brain disorders. J Mol Liq 350:118549. https://doi.org/10.1016/J.MOLLIQ.2022.118549
doi: 10.1016/J.MOLLIQ.2022.118549
Xie J, Shen Z, Anraku Y, Kataoka K, Chen X (2019) Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224:119491. https://doi.org/10.1016/j.biomaterials.2019.119491
doi: 10.1016/j.biomaterials.2019.119491
pubmed: 31546096
pmcid: 6915305
Liu H-J, Xu P (2022) Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. Adv Drug Deliv Rev 191:114619. https://doi.org/10.1016/j.addr.2022.114619
doi: 10.1016/j.addr.2022.114619
pubmed: 36372301
pmcid: 9724744
Liu Y, Li J, Shao K, Huang R, Ye L, Lou J, Jiang C (2010) A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31:5246–5257. https://doi.org/10.1016/J.BIOMATERIALS.2010.03.011
doi: 10.1016/J.BIOMATERIALS.2010.03.011
pubmed: 20382424
Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR, Reis S (2020) RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer’s disease. Pharm Res 37:139. https://doi.org/10.1007/s11095-020-02865-1
doi: 10.1007/s11095-020-02865-1
pubmed: 32661727
Han B, Xie W, Zhang Y, Zhou S, Yang J, Wang R, Sun Y, Wang X, Xu J, Chen D, Wang Y, Lu J, Ning F, Shen F, Liu M, Cai H, Xin H, Lu W, Zhang X (2020) The influx/efflux mechanisms of d-peptide ligand of nAChRs across the blood–brain barrier and its therapeutic value in treating glioma. J Control Release 327:384–396. https://doi.org/10.1016/J.JCONREL.2020.08.010
doi: 10.1016/J.JCONREL.2020.08.010
pubmed: 32791079
Huey R, O’Haga B, McCarron P, Hawthorne S (2017) Targeted drug delivery system to neural cells utilizes the nicotinic acetylcholine receptor. Int J Pharm 525:12–20. https://doi.org/10.1016/j.ijpharm.2017.04.023
Koepsell H (2020) Glucose transporters in brain in health and disease. Pflugers Arch - Eur J Physiol 472:1299–1343. https://doi.org/10.1007/s00424-020-02441-x
Min HS, Kim HJ, Naito M, Ogura S, Toh K, Hayashi K, Kim BS, Fukushima S, Anraku Y, Miyata K, Kataoka K (2020) Systemic brain delivery of antisense oligonucleotides across the blood–brain barrier with a glucose-coated polymeric nanocarrier. Angewandte Chemie - Int Ed 59:8173–8180. https://doi.org/10.1002/ANIE.201914751
doi: 10.1002/ANIE.201914751
Paterson J, Webster CI (2016) Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol 20:49–52. https://doi.org/10.1016/j.ddtec.2016.07.009
doi: 10.1016/j.ddtec.2016.07.009
pubmed: 27986223
Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Frédé F, Calon F (2019) Transferrin receptor-mediated uptake at the blood–brain barrier is not impaired by Alzheimer’s disease neuropathology. https://doi.org/10.1021/acs.molpharmaceut.8b00870
Jain A, Jain A, Garg NK, Tyagi RK, Singh B, Katare OP, Webster TJ, Soni V (2015) Surface engineered polymeric nanocarriers mediate the delivery of transferrin–methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater 24:140–151. https://doi.org/10.1016/J.ACTBIO.2015.06.027
doi: 10.1016/J.ACTBIO.2015.06.027
pubmed: 26116986
Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli MA (2012) Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7:365–382. https://doi.org/10.2217/NNM.11.98
doi: 10.2217/NNM.11.98
pubmed: 21957863
Kuo YC, Wang IH, Rajesh R (2021) Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson’s disease therapy. Acta Biomater 119:360–374. https://doi.org/10.1016/J.ACTBIO.2020.11.015
doi: 10.1016/J.ACTBIO.2020.11.015
pubmed: 33189953
Ulbrich K, Knobloch T, Kreuter J (2010) Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). 19:125–132. https://doi.org/10.3109/10611861003734001
Rhea EM, Rask-Madsen C, Banks WA (2018) Insulin transport across the blood-brain barrier can occur independently of the insulin receptor. J Physiol 596:4753–4765. https://doi.org/10.1113/JP276149
doi: 10.1113/JP276149
pubmed: 30044494
pmcid: 6166047
Kuo YC, Shih-Huang CY (2013) Solid lipid nanoparticles carrying chemotherapeutic drug across the blood–brain barrier through insulin receptor-mediated pathway. J Drug Target 21:730–738. https://doi.org/10.3109/1061186X.2013.812094
doi: 10.3109/1061186X.2013.812094
pubmed: 23815407
Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS (2010) Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30:777–789. https://doi.org/10.1007/S10875-010-9468-4/TABLES/1
doi: 10.1007/S10875-010-9468-4/TABLES/1
pubmed: 20886282
pmcid: 2970823
Nelke C, Spatola M, Schroeter CB, Wiendl H, Lünemann JD (2022) Neonatal Fc receptor–targeted therapies in neurology. Neurotherapeutics 19:729–740. https://doi.org/10.1007/S13311-021-01175-7/TABLES/2
doi: 10.1007/S13311-021-01175-7/TABLES/2
pubmed: 34997443
pmcid: 9294083
Herz J (2003) LRP: a bright beacon at the blood-brain barrier. J Clin Invest 112:1483–1485. https://doi.org/10.1172/JCI20337
doi: 10.1172/JCI20337
pubmed: 14617749
pmcid: 259136
Andrade S, Loureiro JA, Ramalho MJ, Habib S, Singh M (2022) Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review. Polymers 14:712. https://doi.org/10.3390/POLYM14040712
doi: 10.3390/POLYM14040712
Guo Q, Zhu Q, Miao T, Tao J, Ju X, Sun Z, Li H, Xu G, Chen H, Han L (2019) LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. J Control Release 303:117–129. https://doi.org/10.1016/J.JCONREL.2019.04.031
doi: 10.1016/J.JCONREL.2019.04.031
pubmed: 31026546
Agarwal M, Sahoo AK, Bose B (2017) Receptor-mediated enhanced cellular delivery of nanoparticles using recombinant receptor-binding domain of diphtheria toxin. Mol Pharm 14:23–30. https://doi.org/10.1021/ACS.MOLPHARMACEUT.6B00480/SUPPL_FILE/MP6B00480_SI_001.PDF
doi: 10.1021/ACS.MOLPHARMACEUT.6B00480/SUPPL_FILE/MP6B00480_SI_001.PDF
pubmed: 27959571
Srimanee A, Regberg J, Hällbrink M, Vajragupta O, Langel Ü (2016) Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood–brain barrier model. Int J Pharm 500:128–135. https://doi.org/10.1016/J.IJPHARM.2016.01.014
doi: 10.1016/J.IJPHARM.2016.01.014
pubmed: 26773601
Kim C, Kong G, Lee H, Tran Q, Vo TTT, Kwon SH, Park J, Kim SH, Park J (2022) Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma. Toxicol Res 38:249–256. https://doi.org/10.1007/S43188-022-00125-5/METRICS
doi: 10.1007/S43188-022-00125-5/METRICS
pubmed: 35419275
pmcid: 8960497
Wang X, Hawkins BT, Miller DS (2011) Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J 25:644–652. https://doi.org/10.1096/FJ.10-169227
doi: 10.1096/FJ.10-169227
pubmed: 21048045
pmcid: 3023393
Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. 34:47–54. https://doi.org/10.1081/DMR-120001389
Hutter E, Boridy S, Labrecque S, Lalancette-Hébert M, Kriz J, Winnik FM, Maysinger D (2010) Microglial response to gold nanoparticles. ACS Nano 4:2595–2606. https://doi.org/10.1021/NN901869F/SUPPL_FILE/NN901869F_SI_001.PDF
doi: 10.1021/NN901869F/SUPPL_FILE/NN901869F_SI_001.PDF
pubmed: 20329742
Papa S, Rossi F, Ferrari R, Mariani A, De Paola M, Caron I, Fiordaliso F, Bisighini C, Sammali E, Colombo C, Gobbi M, Canovi M, Lucchetti J, Peviani M, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P (2013) Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. https://doi.org/10.1021/nn4036014
Zhang F, Mastorakos P, Mishra MK, Mangraviti A, Hwang L, Zhou J, Hanes J, Brem H, Olivi A, Tyler B, Kannan RM (2015) Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials 52:507–516. https://doi.org/10.1016/J.BIOMATERIALS.2015.02.053
doi: 10.1016/J.BIOMATERIALS.2015.02.053
pubmed: 25818456
pmcid: 4710089
Papa S, Rossi F, Ferrari R, Mariani A, De Paola M, Caron I, Fiordaliso F, Bisighini C, Sammali E, Colombo C, Gobbi M, Canovi M, Lucchetti J, Peviani M, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P (2013) Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. ACS Nano 7:9881–9895. https://doi.org/10.1021/NN4036014/SUPPL_FILE/NN4036014_SI_002.PDF
doi: 10.1021/NN4036014/SUPPL_FILE/NN4036014_SI_002.PDF
pubmed: 24138479
Lamade AM, Kenny EM, Anthonymuthu TS, Soysal E, Clark RSB, Kagan VE, Bayır H (2019) Aiming for the target: mitochondrial drug delivery in traumatic brain injury. Neuropharmacology 145:209–219. https://doi.org/10.1016/J.NEUROPHARM.2018.07.014
doi: 10.1016/J.NEUROPHARM.2018.07.014
pubmed: 30009835
Zhang F, Lin YA, Kannan S, Kannan RM (2016) Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release 240:212–226. https://doi.org/10.1016/J.JCONREL.2015.12.013
doi: 10.1016/J.JCONREL.2015.12.013
pubmed: 26686078
Rungta RL, Choi HB, Lin PJ, Ko RW, Ashby D, Nair J, Manoharan M, Cullis PR, MacVicar BA (2013) Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. https://doi.org/10.1038/mtna.2013.65
Wang P, Zheng X, Guo Q, Yang P, Pang X, Qian K, Lu W, Zhang Q, Jiang X (2018) Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer’s disease. J Control Release 279:220–233. https://doi.org/10.1016/J.JCONREL.2018.04.034
doi: 10.1016/J.JCONREL.2018.04.034
pubmed: 29679667
Handa M, Singh A, Bisht D, Kesharwani P, Shukla R (2022) Potential of particle size less than 15 nm via olfactory region for direct brain delivery via intranasal route. Health Sci Rev 4:100038. https://doi.org/10.1016/J.HSR.2022.100038
doi: 10.1016/J.HSR.2022.100038
Wang L, Tang S, Yu Y, Lv Y, Wang A, Yan X, Li N, Sha C, Sun K, Li Y (2021) Intranasal delivery of temozolomide-conjugated gold nanoparticles functionalized with anti-EphA3 for glioblastoma targeting. Mol Pharm 18:915–927. https://doi.org/10.1021/ACS.MOLPHARMACEUT.0C00911/SUPPL_FILE/MP0C00911_SI_001.PDF
doi: 10.1021/ACS.MOLPHARMACEUT.0C00911/SUPPL_FILE/MP0C00911_SI_001.PDF
pubmed: 33417456
Tang S, Wang A, Yan X, Chu L, Yang X, Song Y, Sun K, Yu X, Liu R, Wu Z, Xue P (2019) Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease. Drug Deliv 26:700–707. https://doi.org/10.1080/10717544.2019.1636420
doi: 10.1080/10717544.2019.1636420
pubmed: 31290705
pmcid: 7577045
Das UN, Prasad VVSK, Reddy DR (1995) Local application of γ-linolenic acid in the treatment of human gliomas. Cancer Lett 94:147–155. https://doi.org/10.1016/0304-3835(95)03844-M
doi: 10.1016/0304-3835(95)03844-M
pubmed: 7634242
Cai L, Yang C, Jia W, Liu Y, Xie R, Lei T, Yang Z, He X, Tong R, Gao H (2020) Endo/lysosome-escapable delivery depot for improving BBB transcytosis and neuron targeted therapy of Alzheimer’s disease. Adv Funct Mater 30:1909999. https://doi.org/10.1002/ADFM.201909999
doi: 10.1002/ADFM.201909999
Gumerlock MK, Belshe BD, Madsen R, Watts C (1992) Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 12:33–46. https://doi.org/10.1007/BF00172455/METRICS
doi: 10.1007/BF00172455/METRICS
pubmed: 1541977
Li C, Chen LL, Wang YY, Wang TT, Di D, Zhang H, Zhao HH, Shen X, Guo J (2021) Protein nanoparticle-related osmotic pressure modifies nonselective permeability of the blood-brain barrier by increasing membrane fluidity. Int J Nanomed 16:1663–1680. https://doi.org/10.2147/IJN.S291286
doi: 10.2147/IJN.S291286
Rich MC, Sherwood J, Bartley AF, Whitsitt QA, Lee M, Willoughby WR, Dobrunz LE, Bao Y, Lubin FD, Bolding M (2020) Focused ultrasound blood brain barrier opening mediated delivery of MRI-visible albumin nanoclusters to the rat brain for localized drug delivery with temporal control. J Control Release 324:172–180. https://doi.org/10.1016/J.JCONREL.2020.04.054
doi: 10.1016/J.JCONREL.2020.04.054
pubmed: 32376461
pmcid: 8890744
Song Z, Huang X, Wang J, Cai F, Zhao P, Yan F (2021) Targeted delivery of liposomal temozolomide enhanced anti-glioblastoma efficacy through ultrasound-mediated blood–brain barrier opening. Pharmaceutics 13:1270. https://doi.org/10.3390/PHARMACEUTICS13081270
doi: 10.3390/PHARMACEUTICS13081270
pubmed: 34452234
pmcid: 8401148
Ficiarà E, Ansari SA, Argenziano M, Cangemi L, Monge C, Cavalli R, D’Agata F (2020) Beyond oncological hyperthermia: physically drivable magnetic nanobubbles as novel multipurpose theranostic carriers in the central nervous system. Molecules 25:2104. https://doi.org/10.3390/MOLECULES25092104
doi: 10.3390/MOLECULES25092104
pubmed: 32365941
pmcid: 7248690
Bennett C, Samikkannu M, Mohammed F, Dietrich WD, Rajguru SM, Prasad A (2018) Blood brain barrier (BBB)-disruption in intracortical silicon microelectrode implants. Biomaterials 164:1. https://doi.org/10.1016/J.BIOMATERIALS.2018.02.036
doi: 10.1016/J.BIOMATERIALS.2018.02.036
pubmed: 29477707
pmcid: 5895107
Markowicz-Piasecka M, Darłak P, Markiewicz A, Sikora J, Kumar Adla S, Bagina S, Huttunen KM (2022) Current approaches to facilitate improved drug delivery to the central nervous system. Eur J Pharm Biopharm 181:249–262. https://doi.org/10.1016/J.EJPB.2022.11.003
doi: 10.1016/J.EJPB.2022.11.003
pubmed: 36372271
Lalatsa A, Lee V, Malkinson JP, Zloh M, Schä AG, Uchegbu IF (2012) A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine 5-enkephalin, to the brain. https://doi.org/10.1021/mp300009u
Ju X, Chen H, Miao T, Ni J, Han L (2021) Prodrug delivery using dual-targeting nanoparticles to treat breast cancer brain metastases. Mol Pharm 18:2694–2702. https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00224/ASSET/IMAGES/LARGE/MP1C00224_0006.JPEG
doi: 10.1021/ACS.MOLPHARMACEUT.1C00224/ASSET/IMAGES/LARGE/MP1C00224_0006.JPEG
pubmed: 34109794
Zhou X, Smith QR, Liu X (2021) Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 13. https://doi.org/10.1002/WNAN.1695
Sánchez-Navarro M, Giralt E (2022) Peptide shuttles for blood–brain barrier drug delivery. Pharmaceutics 14:1874. https://doi.org/10.3390/PHARMACEUTICS14091874
doi: 10.3390/PHARMACEUTICS14091874
pubmed: 36145622
pmcid: 9505527
Faresjö R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syvänen S (2021) Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS 18:1–15. https://doi.org/10.1186/S12987-021-00257-0/FIGURES/7
doi: 10.1186/S12987-021-00257-0/FIGURES/7
Aktaş Y, Yemisci M, Andrieux K, Neslihan Gürsoy R, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, Hamdi H, Celik AS, Demir AA, Hincal T, Dalkara Y, Capan P. Couvreur (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16:1503–11. https://doi.org/10.1021/bc050217o
doi: 10.1021/bc050217o
pubmed: 16287248
Kuo YC, Ko HF (2013) Targeting delivery of saquinavir to the brain using 83–14 monoclonal antibody-grafted solid lipid nanoparticles. Biomaterials 34:4818–4830. https://doi.org/10.1016/J.BIOMATERIALS.2013.03.013
doi: 10.1016/J.BIOMATERIALS.2013.03.013
pubmed: 23545288
Huang X, Shi S, Wang H, Zhao T, Wang Y, Huang S, Su Y, Zhao C, Yang M (2023) Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas. Int Immunopharmacol 117:109990. https://doi.org/10.1016/J.INTIMP.2023.109990
doi: 10.1016/J.INTIMP.2023.109990
pubmed: 37012874
Taib T, Leconte C, Van Steenwinckel J, Cho AH, Palmier B, Torsello E, Kuen RL, Onyeomah S, Ecomard K, Benedetto C, Coqueran B, Novak AC, Deou E, Plotkine M, Gressens P, Marchand-Leroux C, Besson VC (2017) Neuroinflammation, myelin and behavior: temporal patterns following mild traumatic brain injury in mice. PLoS One 12. https://doi.org/10.1371/JOURNAL.PONE.0184811 .
Paz AA, González-Candia A (2023) Potential pharmacological target of tight junctions to improve the BBB permeability in neonatal hypoxic-ischemic encephalopathy diseases. Biochem Pharmacol 207:115356. https://doi.org/10.1016/j.bcp.2022.115356
doi: 10.1016/j.bcp.2022.115356
pubmed: 36455671
Nian K, Harding IC, Herman IM, Ebong EE (2020) Blood-brain barrier damage in ischemic stroke and its regulation by endothelial mechanotransduction. Front Physiol 11:1681. https://doi.org/10.3389/FPHYS.2020.605398/BIBTEX
doi: 10.3389/FPHYS.2020.605398/BIBTEX
Sivandzade F, Alqahtani F, Cucullo L (2020) Traumatic brain injury and blood–brain barrier (BBB): underlying pathophysiological mechanisms and the influence of cigarette smoking as a premorbid condition. Int J Mol Sci 21:2721. https://doi.org/10.3390/IJMS21082721
doi: 10.3390/IJMS21082721
pubmed: 32295258
pmcid: 7215684
Rempe RG, Hartz AMS, Bauer B (2016) Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab 36(9):1481–1507. https://doi.org/10.1177/0271678X16655551
Liao R, Wood TR, Nance E (2020) Nanotherapeutic modulation of excitotoxicity and oxidative stress in acute brain injury. Nanobiomedicine (Rij) 7. https://doi.org/10.1177/1849543520970819
Unterberg AW, Stover J, Kress B, Kiening KL (2004) Edema and brain trauma. Neuroscience 129:1019–1027. https://doi.org/10.1016/J.NEUROSCIENCE.2004.06.046
doi: 10.1016/J.NEUROSCIENCE.2004.06.046
Yang Y, Torbey MT (2020) Angiogenesis and blood-brain barrier permeability in vascular remodeling after stroke. Curr Neuropharmacol 18:1250–1265. https://doi.org/10.2174/1570159X18666200720173316
doi: 10.2174/1570159X18666200720173316
pubmed: 32691713
pmcid: 7770645
Saeedi M, Eslamifar M, Khezri K, Dizaj SM (2019) Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother 111:666–675. https://doi.org/10.1016/j.biopha.2018.12.133
doi: 10.1016/j.biopha.2018.12.133
pubmed: 30611991
Debbage P, Thurner GC (2010) Nanomedicine faces barriers. Pharmaceuticals 3:3371. https://doi.org/10.3390/PH3113371
doi: 10.3390/PH3113371
pmcid: 4034073
Chen Y, Liu L (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64:640–665. https://doi.org/10.1016/J.ADDR.2011.11.010
doi: 10.1016/J.ADDR.2011.11.010
pubmed: 22154620
Jhaveri A, Deshpande P, Pattni B, Torchilin V (2018) Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release 277:89–101. https://doi.org/10.1016/J.JCONREL.2018.03.006
doi: 10.1016/J.JCONREL.2018.03.006
pubmed: 29522834
pmcid: 5911193
Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M (2014) Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget 5:10446. https://doi.org/10.18632/ONCOTARGET.2182
doi: 10.18632/ONCOTARGET.2182
pubmed: 25431953
pmcid: 4279385
Lv Q, Li LM, Han M, Tang XJ, Yao JN, Ying XY, Li FZ, Gao JQ (2013) Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. Int J Pharm 444:1–9. https://doi.org/10.1016/J.IJPHARM.2013.01.025
doi: 10.1016/J.IJPHARM.2013.01.025
pubmed: 23347891
Sonali, Singh RP, Singh N, Sharma G, Vijayakumar MR, Koch B, Singh S, Singh U, Dash D, Pandey BL, Muthu MS (2016) Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. Drug Deliv 23:1261–1271. https://doi.org/10.3109/10717544.2016.1162878
doi: 10.3109/10717544.2016.1162878
pubmed: 26961144
Wong HL, Wu XY, Bendayan R(2011) Nanotechnological advances for the delivery of CNS therapeutics. https://doi.org/10.1016/j.addr.2011.10.007
Rip J, Chen L, Hartman R, van den Heuvel A, Reijerkerk A, van Kregten J, van der Boom B, Appeldoorn C, de Boer M, Maussang D, de Lange ECM, Gaillard PJ (2014) Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats. J Drug Target 22:460–467. https://doi.org/10.3109/1061186X.2014.888070
doi: 10.3109/1061186X.2014.888070
pubmed: 24524555
pmcid: 4651142
Qin Y, Chen H, Yuan W, Kuai R, Zhang Q, Xie F, Zhang L, Zhang Z, Liu J, He Q (2011) Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 419:85–95. https://doi.org/10.1016/j.ijpharm.2011.07.021
doi: 10.1016/j.ijpharm.2011.07.021
pubmed: 21807083
Tamaru M, Akita H, Fujiwara T, Kajimoto K, Harashima H (2010) Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochem Biophys Res Commun 394:587–592. https://doi.org/10.1016/j.bbrc.2010.03.024
doi: 10.1016/j.bbrc.2010.03.024
pubmed: 20214882
Sonali P, Agrawal RP, Singh CV, Rajesh S, Singh MR, Vijayakumar BL, Pandey M.S. Muthu (2016) Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug Deliv 23:1788–1798. https://doi.org/10.3109/10717544.2015.1094681
doi: 10.3109/10717544.2015.1094681
pubmed: 26431064
Niu J, Wang A, Ke Z, Zheng Z (2014) Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating. J Drug Target 22:712–723. https://doi.org/10.3109/1061186X.2014.913052
doi: 10.3109/1061186X.2014.913052
pubmed: 24806516
Zhan C, Li B, Hu L, Wei X, Feng L, Fu W, Lu W (2011) Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed 50:5482–5485. https://doi.org/10.1002/anie.201100875
doi: 10.1002/anie.201100875
Qiao R, Jia Q, Hüwel S, Xia R, Liu T, Gao F, Galla H-J, Gao M (2012) Receptor-mediated delivery of magnetic nanoparticles across the blood–brain barrier. ACS Nano 6:3304–3310. https://doi.org/10.1021/nn300240p
doi: 10.1021/nn300240p
pubmed: 22443607
Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X (2012) Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33:5414–5422. https://doi.org/10.1016/J.BIOMATERIALS.2012.04.032
doi: 10.1016/J.BIOMATERIALS.2012.04.032
pubmed: 22560667
pmcid: 3577933
Handa M, Tiwari S, Yadav AK, Almalki WH, Alghamdi S, Alharbi KS, Shukla R, Beg S (2021) Therapeutic potential of nanoemulsions as feasible wagons for targeting Alzheimer’s disease. Drug Discov Today 26:2881–2888. https://doi.org/10.1016/J.DRUDIS.2021.07.020
doi: 10.1016/J.DRUDIS.2021.07.020
pubmed: 34332094
Afzal SM, Shareef MZ, Kishan V (2016) Transferrin tagged lipid nanoemulsion of docetaxel for enhanced tumor targeting. J Drug Deliv Sci Technol 36:175–182. https://doi.org/10.1016/J.JDDST.2016.10.008
doi: 10.1016/J.JDDST.2016.10.008
Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM (2013) Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother 10:321–332. https://doi.org/10.4161/HV.26796
doi: 10.4161/HV.26796
pubmed: 24128651
pmcid: 4185908
Patel T, Zhou J, Piepmeier JM, Saltzman WM (2012) Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 64:701. https://doi.org/10.1016/J.ADDR.2011.12.006
doi: 10.1016/J.ADDR.2011.12.006
pubmed: 22210134
Patel PJ, Acharya NS, Acharya SR(2013) Development and characterization of glutathione-conjugated albumin nanoparticles for improved brain delivery of hydrophilic fluorescent marker. 20:143–155 https://doi.org/10.3109/10717544.2013.801050
Dieu LH, Wu D, Palivan CG, Balasubramanian V, Huwyler J (2014) Polymersomes conjugated to 83–14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells. Eur J Pharm Biopharm 88:316–324. https://doi.org/10.1016/J.EJPB.2014.05.021
doi: 10.1016/J.EJPB.2014.05.021
pubmed: 24929212
Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL (2010) Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 31:908–915. https://doi.org/10.1016/J.BIOMATERIALS.2009.09.104
doi: 10.1016/J.BIOMATERIALS.2009.09.104
pubmed: 19853292
Xie H, Zhu Y, Jiang W, Zhou Q, Yang H, Gu N, Zhang Y, Xu H, Xu H, Yang X (2011) Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32:495–502. https://doi.org/10.1016/J.BIOMATERIALS.2010.09.024
doi: 10.1016/J.BIOMATERIALS.2010.09.024
pubmed: 20970851
Pereira P, Barreira M, Cruz C, Tomás J, Luís Â, Pedro AQ, Queiroz JA, Sousa F (2020) Brain-targeted delivery of pre-miR-29b using lactoferrin-stearic acid-modified-chitosan/polyethyleneimine polyplexes. Pharmaceuticals 13:314. https://doi.org/10.3390/PH13100314
doi: 10.3390/PH13100314
pubmed: 33076502
pmcid: 7602608
Kuo YC, Chen YC (2015) Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles. Int J Pharm 479:138–149. https://doi.org/10.1016/J.IJPHARM.2014.12.070
doi: 10.1016/J.IJPHARM.2014.12.070
pubmed: 25560309
Kang Z, Zeng C, Tian L, Wang T, Yang S, Cheng Q, Zhang J, Meng Q, Zhang C, Meng Z (2022) Transferrin receptor targeting segment T7 containing peptide gene delivery vectors for efficient transfection of brain tumor cells. Drug Deliv 29:2375–2385. https://doi.org/10.1080/10717544.2022.2102696
doi: 10.1080/10717544.2022.2102696
pubmed: 35866298
pmcid: 9310815
Kim JY, Choi WIL, Kim YH, Tae G (2013) Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 34:1170–1178. https://doi.org/10.1016/J.BIOMATERIALS.2012.09.047
doi: 10.1016/J.BIOMATERIALS.2012.09.047
pubmed: 23122677
Kuo YC, Chung CY (2012) Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells. Colloids Surf B Biointerfaces 91:242–249. https://doi.org/10.1016/J.COLSURFB.2011.11.007
doi: 10.1016/J.COLSURFB.2011.11.007
pubmed: 22137614
Patel M, Souto EB, Singh KK (2013) Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 10:889–905. https://doi.org/10.1517/17425247.2013.784742
doi: 10.1517/17425247.2013.784742
pubmed: 23550609
Neves AR, Queiroz JF, Lima SAC, Reis S (2017) Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery: uptake mechanism and transport pathways. Bioconjug Chem 28:995–1004. https://doi.org/10.1021/ACS.BIOCONJCHEM.6B00705/ASSET/IMAGES/MEDIUM/BC-2016-00705F_0007.GIF
doi: 10.1021/ACS.BIOCONJCHEM.6B00705/ASSET/IMAGES/MEDIUM/BC-2016-00705F_0007.GIF
pubmed: 28355061
Zwain T, Alder JE, Sabagh B, Shaw A, Burrow AJ, Singh KK (2021) Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB / BBTB models. Mater Sci Eng C 121:111774. https://doi.org/10.1016/j.msec.2020.111774
Zwain T, Alder JE, Zwayen S, Shaw A, Burrow AJ, Singh KK (2023) Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy. Biomaterials Advances 155:213660. https://doi.org/10.1016/J.BIOADV.2023.213660
doi: 10.1016/J.BIOADV.2023.213660
pubmed: 37976832
Tang WL, Tang WH, Li SD (2018) Cancer theranostic applications of lipid-based nanoparticles. Drug Discov Today 23:1159–1166. https://doi.org/10.1016/J.DRUDIS.2018.04.007
doi: 10.1016/J.DRUDIS.2018.04.007
pubmed: 29660478
Peng H, Liu X, Wang G, Li M, Bratlie KM, Cochran E, Wang Q (2015) Polymeric multifunctional nanomaterials for theranostics. J Mater Chem B 3:6856–6870. https://doi.org/10.1039/C5TB00617A
doi: 10.1039/C5TB00617A
pubmed: 32262535
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–522. https://doi.org/10.1016/J.JCONREL.2012.01.043
doi: 10.1016/J.JCONREL.2012.01.043
pubmed: 22353619
Wu X, Chen G, Shen J, Li Z, Zhang Y, Han G(2014) Upconversion nanoparticles: a versatile solution to multiscale biological imaging. https://doi.org/10.1021/bc5003967
Hilderbrand SA, Weissleder R (2010) Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol 14:71–79. https://doi.org/10.1016/J.CBPA.2009.09.029
doi: 10.1016/J.CBPA.2009.09.029
pubmed: 19879798
Vardharajula S, Ali SZ, Tiwari PM, Eroǧlu E, Vig K, Dennis VA, Singh SR (2012) Functionalized carbon nanotubes: biomedical applications. Int J Nanomed 7:5361–5374. https://doi.org/10.2147/IJN.S35832
doi: 10.2147/IJN.S35832
Gamage NH, Li J, Worsham MJ, Ali MM (2016) Targeted theranostic approach for glioma using dendrimer-based curcumin nanoparticle. J Nanomed Nanotechnol 7:393. https://doi.org/10.4172/2157-7439.1000393
doi: 10.4172/2157-7439.1000393
pubmed: 27699139
pmcid: 5040461
Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF (2013) Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev 65:121–138. https://doi.org/10.1016/J.ADDR.2012.09.041
doi: 10.1016/J.ADDR.2012.09.041
pubmed: 23026636
Schöttler S, Becker G, Winzen S, Steinbach T, Mohr K, Landfester K, Mailänder V, Wurm FR (2016) Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat Nanotechnol 11:372–377. https://doi.org/10.1038/NNANO.2015.330
doi: 10.1038/NNANO.2015.330
pubmed: 26878141
Loch-Neckel G, Matos AT, Vaz AR, Brites D (2022) Challenges in the development of drug delivery systems based on small extracellular vesicles for therapy of brain diseases. Front Pharmacol 13:733. https://doi.org/10.3389/FPHAR.2022.839790/BIBTEX
doi: 10.3389/FPHAR.2022.839790/BIBTEX
Choi H, Choi K, Kim DH, Oh BK, Yim H, Jo S, Choi C (2022) Strategies for targeted delivery of exosomes to the brain: advantages and challenges. Pharmaceutics 14:672. https://doi.org/10.3390/PHARMACEUTICS14030672
doi: 10.3390/PHARMACEUTICS14030672
pubmed: 35336049
pmcid: 8948948
Alexander A, Agrawal M, Uddin A, Siddique S, Shehata AM, Shaker MA, Rahman SAU, Abdul MIM, Shaker MA (2019) Recent expansions of novel strategies towards the drug targeting into the brain. Int J Nanomed 14:5895–5909. https://doi.org/10.2147/IJN.S210876
doi: 10.2147/IJN.S210876
Ganipineni LP, Danhier F, Préat V (2018) Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. J Control Release 281:42–57. https://doi.org/10.1016/J.JCONREL.2018.05.008
doi: 10.1016/J.JCONREL.2018.05.008
pubmed: 29753958
Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C, Jauch-Worley T, Kölbl O, Pietsch T, Proescholdt M, Rümmele P, Muigg A, Stockhammer G, Hegi M, Bogdahn U, Hau P (2009) RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma–a phase II study. BMC Cancer 9:308. https://doi.org/10.1186/1471-2407-9-308
doi: 10.1186/1471-2407-9-308
pubmed: 19725960
pmcid: 2749868
Verry C, Sancey L, Dufort S, Le Duc G, Mendoza C, Lux F, Grand S, Arnaud J, Quesada JL, Villa J, Tillement O, Balosso J (2019) Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. BMJ Open 9:e023591. https://doi.org/10.1136/BMJOPEN-2018-023591
doi: 10.1136/BMJOPEN-2018-023591
pubmed: 30755445
pmcid: 6377538
Verry C, Dufort S, Lemasson B, Grand S, Pietras J, Troprès I, Crémillieux Y, Lux F, Mériaux S, Larrat B, Balosso J, Le Duc G, Barbier EL, Tillement O (2020) Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci Adv 6. https://doi.org/10.1126/SCIADV.AAY5279/SUPPL_FILE/AAY5279_SM.PDF
Goldberg MS, Hook SS, Wang AZ, Bulte JWM, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ (2013) Biotargeted nanomedicines for cancer: six tenets before you begin. 8:299–308 https://doi.org/10.2217/NNM.13.3
Ragelle H, Danhier F, Préat V, Langer R, Anderson DG(2016) Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. 14:851–864 https://doi.org/10.1080/17425247.2016.1244187
Khan AR, Liu M, Khan MW, Zhai G (2017) Progress in brain targeting drug delivery system by nasal route. J Control Release 268:364–389. https://doi.org/10.1016/J.JCONREL.2017.09.001
doi: 10.1016/J.JCONREL.2017.09.001
pubmed: 28887135
Du L, Empey PE, Ji J, Chao H, Kochanek PM, Baylr H, Clark RSB (2016) Probenecid and N-acetylcysteine prevent loss of intracellular glutathione and inhibit neuronal death after mechanical stretch injury in vitro. J Neurotrauma 33:1913–1917. https://doi.org/10.1089/NEU.2015.4342
doi: 10.1089/NEU.2015.4342
pubmed: 26830358
pmcid: 5079409
Dwivedi P, Kansal S, Sharma M, Shukla R, Verma A, Shukla P, Tripathi P, Gupta P, Saini D, Khandelwal K, Verma R, Dwivedi AK, Mishra PR (2012) Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. J Drug Target 20:883–896. https://doi.org/10.3109/1061186X.2012.725169
doi: 10.3109/1061186X.2012.725169
pubmed: 23020515
Patel V, Chavda V, Shah J (2020) Nanotherapeutics in neuropathologies: obstacles, challenges and recent advancements in CNS targeted drug delivery systems. Curr Neuropharmacol 19:693–710. https://doi.org/10.2174/1570159X18666200807143526
doi: 10.2174/1570159X18666200807143526
Ashique S, Afzal O, Yasmin S, Hussain A, Altamimi MA, Webster TJ, Altamimi ASA (2023) Strategic nanocarriers to control neurodegenerative disorders: concept, challenges, and future perspective. Int J Pharm 633:122614. https://doi.org/10.1016/J.IJPHARM.2023.122614
doi: 10.1016/J.IJPHARM.2023.122614
pubmed: 36646255
Chaturvedi A, Sharma S, Shukla R (2023) Nano-mediated molecular targeting in diagnosis and mitigation of Wilson disease. Mol Neurobiol 2023:1–19. https://doi.org/10.1007/S12035-023-03816-8
doi: 10.1007/S12035-023-03816-8
Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J 14:282–295. https://doi.org/10.1208/S12248-012-9339-4/FIGURES/5
doi: 10.1208/S12248-012-9339-4/FIGURES/5
pubmed: 22407288
pmcid: 3326161
Niu X, Chen J, Gao J (2019) Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci 14:480–496. https://doi.org/10.1016/j.ajps.2018.09.005
doi: 10.1016/j.ajps.2018.09.005
pubmed: 32104476
Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H (2019) Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm 565:258–268. https://doi.org/10.1016/J.IJPHARM.2019.05.032
doi: 10.1016/J.IJPHARM.2019.05.032
pubmed: 31095983
Gidwani B, Sahu V, Shukla SS, Pandey R, Joshi V, Jain VK, Vyas A (2021) Quantum dots: prospectives, toxicity, advances and applications. J Drug Deliv Sci Technol 61:102308. https://doi.org/10.1016/J.JDDST.2020.102308
doi: 10.1016/J.JDDST.2020.102308
Tapeinos C, Battaglini M, Ciofani G (2017) Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 264:306–332. https://doi.org/10.1016/J.JCONREL.2017.08.033
doi: 10.1016/J.JCONREL.2017.08.033
pubmed: 28844756
pmcid: 6701993
Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for brain targeting. Biomolecules 9:790. https://doi.org/10.3390/BIOM9120790
doi: 10.3390/BIOM9120790
pubmed: 31783573
pmcid: 6995517
Achar A, Myers R, Ghosh C (2021) Drug delivery challenges in brain disorders across the blood–brain barrier: novel methods and future considerations for improved therapy. Biomedicines 9:1834. https://doi.org/10.3390/BIOMEDICINES9121834
doi: 10.3390/BIOMEDICINES9121834
pubmed: 34944650
pmcid: 8698904
Tang L, Feng Y, Gao S, Mu Q, Liu C (2021) Nanotherapeutics overcoming the blood-brain barrier for glioblastoma treatment. Front Pharmacol 12:3418. https://doi.org/10.3389/FPHAR.2021.786700/BIBTEX
doi: 10.3389/FPHAR.2021.786700/BIBTEX